TOP TIERMARKET NEWSWIRE
News & sentiment

AKTIS ONCOLOGY INC (AKTS) — News & AI sentiment

AKTIS ONCOLOGY INC (AKTS) news roundup. 6 stories aggregated over the last 30 days. Average 30-day sentiment is 60.3/100. Recent insider activity (SEC Form 4, 90-day window): 0 purchases totalling $0 and 4 sales totalling $3.0M — net selling of $3.0M. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
6
avg sentiment 60.3/100
Insider net (90d)
$3.0M
0 buys · 4 sells
Congress (90d)
0
0 buys · 0 sells

AKTS news in the last 24 hours, 7 days, 30 days and 90 days

How much AKTS coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowAKTS storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days660.3/100AKTS headlines →
Last 90 days1459.4/100AKTS headlines →

Latest stories on AKTS

Sep 16
Sep 9
Sep 9
Sep 9
Oppenheimer initiates Aktis Oncology stock rating at Outperform
Investing.com Analyst Ratings63 · neutralanalyst
Sep 9
Sep 9
Wedbush initiates Aktis Oncology stock with outperform rating
Investing.com Analyst Ratings61 · neutralanalyst
Aug 19
Aug 19
Aug 19
Aug 18
Aug 16
Aktis Oncology, Inc. (AKTS) files 8-K
SEC 8-K50 · neutralgeneral
Aug 13
Aug 13
Aug 13
Jun 25
Jun 16
Jun 12
Aktis Oncology: Mini-Proteins With A Targeted Punch
Seeking Alpha59 · neutralproduct/pr
Jun 11
May 27
May 21
Open AKTS in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →